2,227 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Heritage Wealth Management LLC

Heritage Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,227 shares of the company’s stock, valued at approximately $1,298,000.

Other institutional investors have also recently bought and sold shares of the company. Robertson Stephens Wealth Management LLC increased its stake in Eli Lilly and Company by 30.6% in the 4th quarter. Robertson Stephens Wealth Management LLC now owns 4,145 shares of the company’s stock valued at $2,416,000 after buying an additional 971 shares during the period. McIlrath & Eck LLC increased its position in Eli Lilly and Company by 16.5% in the 4th quarter. McIlrath & Eck LLC now owns 465 shares of the company’s stock worth $271,000 after purchasing an additional 66 shares during the last quarter. Fortitude Advisory Group L.L.C. grew its position in Eli Lilly and Company by 14.8% in the fourth quarter. Fortitude Advisory Group L.L.C. now owns 2,316 shares of the company’s stock worth $1,350,000 after acquiring an additional 298 shares in the last quarter. First Trust Direct Indexing L.P. lifted its position in shares of Eli Lilly and Company by 18.8% in the fourth quarter. First Trust Direct Indexing L.P. now owns 15,374 shares of the company’s stock worth $8,962,000 after buying an additional 2,433 shares during the last quarter. Finally, New York Life Investment Management LLC boosted its stake in shares of Eli Lilly and Company by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 126,377 shares of the company’s stock worth $73,668,000 after acquiring an additional 836 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.3 %

LLY traded down $10.45 during midday trading on Thursday, reaching $766.30. 921,736 shares of the company were exchanged, compared to its average volume of 3,041,964. The stock has a market capitalization of $728.11 billion, a P/E ratio of 113.06, a PEG ratio of 1.58 and a beta of 0.37. Eli Lilly and Company has a one year low of $414.31 and a one year high of $800.78. The stock’s 50-day simple moving average is $762.03 and its 200 day simple moving average is $669.96. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 earnings per share. The business’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, analysts forecast that Eli Lilly and Company will post 13.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Truist Financial raised their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, Barclays upped their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.